# SELARSDI (selarsdi) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/selarsdi

> The FDA approved SELARSDI (selarsdi), sponsored by TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), on October 22, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is SELARSDI (selarsdi) FDA approved?

Yes. The FDA approved SELARSDI (selarsdi), sponsored by TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), on October 22, 2024. Press release filed with the SEC (EX-99): "On October 22, 2024, the FDA approved SELARSDI in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion, expanding its label to include the treatment of adults with Crohn's disease and ulcerative colitis." [Calendar and source filings](https://sec-api.dev/pdufa/selarsdi)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-381899, https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm (retrieved 2026-11-12). Last confirmed 2026-09-03. Cite: https://sec-api.dev/pdufa/selarsdi#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | SELARSDI (selarsdi) |
| Codes |  |
| Sponsor | TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) https://sec-api.dev/companies/teva/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Apr 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-08-13, last confirmed 2025-08-13.
- Press release filed with the SEC (EX-99) (accession 0001898416-25-000009): "Alvotech received approval from the FDA for SELARSDI, AVT04 biosimilar to Stelara, in April 2024." https://www.sec.gov/Archives/edgar/data/1898416/000189841625000009/alvotechq22025-mda.htm

### October 22, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-09-03, last confirmed 2026-09-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-381899): "On October 22, 2024, the FDA approved SELARSDI in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion, expanding its label to include the treatment of adults with Crohn's disease and ulcerative colitis." https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/selarsdi.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SELARSDI (selarsdi) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/selarsdi

```bibtex
@misc{secapidev_pdufa_selarsdi_20261116,
  title        = {SELARSDI (selarsdi) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/selarsdi}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_selarsdi_20261116","title":"SELARSDI (selarsdi) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/selarsdi","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
